TNFRSF18 and melanoma: Similar to GITR agonists, drugs targeting adenosine signaling may have a positive dual function on helper ILCs in the context of melanoma, restoring the anti-tumoral properties of ILC1s and counteracting the potential deleterious effects of ILC2s.